You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 22, 2024

CLINICAL TRIALS PROFILE FOR CYCRIN


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for CYCRIN

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00392093 ↗ Effect of Hormone Replacement Therapy on Lupus Activity Completed Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran Phase 4 1997-11-01 Hypothesis, HRT does not increase the risk of lupus activity exacerbation, it is effective for the relief of menopausal symptoms and improves bone mineral density. Double-blind, randomized, placebo controlled clinical trial. Objectives 1. Determine the effect of HRT on disease activity, menopausal symptoms, bone mineral density, lipid profile, and mammographic parenchymal density in menopausal women with SLE. 2. Determine the incidence rate of major side effects of HRT in menopausal women with SLE. Outcome Measures 1. Primary outcome will be global disease activity throughout the follow-up period. 2. Incidence of lupus flares, time to the first flare, changes in SLEDAI values from baseline at each follow-up visit, maximum disease activity, lupus treatment, hospitalizations, thromboses, and deaths. Menopausal symptoms and depression will be assessed utilizing the Greene Climacteric Scale questionnaire and the Beck Depression Inventory. Bone mineral density of lumbar spine and hip will be performed with dual energy x-ray absorptiometry. In addition, blood and urine samples to measure biochemical markers of bone turnover. Estradiol levels, lipid profile,coagulation tests, cervical cytology examinations, mammography. Inclusion Criteria: (Any two of the following criteria) 1. Amenorrhea of 6 months or more 2. Serum FSH level of 30 IU/L or more 3. Menopausal symptoms 4. Age 48 years or older. Exclusion Criteria: 1. Women older than 65 years 2. Severe lupus activity at baseline 3. Use of estrogens within 3 months of the screening visit 4. Serum creatinine of 2.0 mg/dL or more 5. Hypertriglyceridemia 500 mg/dL or more 6. Metabolic bone diseases 7. Liver disease 8. Untreated hyperthyroidism 9. Recent thrombosis 10. Malignancy 11. Endometrial hyperplasia 12. Undiagnosed uterine bleeding 13. Cervical dysplasia. Subject allocation Random assign, using a computer-generated randomization list to: Conjugated equine estrogens 0.625 mg/day plus 5 mg/day of medroxyprogesterone acetate p.o. for the first 10 days per-month, or biologically inert placebo.All women will receive 1200 mg of calcium carbonate and 800 IU of vitamin D, daily. Follow-up procedure All patients will be evaluated by a rheumatologist and a reproductive health specialist at baseline,1,2,3,6,9,12,15,18,21, and 24 months. Rheumatic evaluation: 1. General information (baseline). 2. Lupus activity (every visit). 3. Medications: (every visit) Gynecological evaluation: Onset of symptoms since the previous visit using a standardized questionnaire. In addition, a gynecological examination will be performed. Criteria for early termination of the study: A patient will be discontinued from the study whenever any of the following criteria would be present: 1. Development of severe lupus activity (SLEDAI > 30). 2. Development of any putative complication to hormone therapy. 3. Development of any other severe complications due neither to SLE nor hormone therapy. 4. Need prolonged immobilization. Statistical analysis: Between-group comparisons of lupus activity, maximum SLEDAI, and change in SLEDAI score from baseline at each follow-up visit. Incidence-density rates of flares with relative risk and 95 percent confidence intervals.Probability of flares throughout the study using life-table analyses and log-rank test. Climacteric symptoms as the mean value of the Green's scale score at baseline and at each follow-up visit, between-group and intra-group. Bone mineral density as the mean value at baseline, 12 and 24 months, between and intra-group. The proportion of patients in each group who develop secondary effects, as well as the number who quit the study during the follow-up period. Continuous variables will be compared using Student's t-test, and categorical variables using chi-square or Fisher's exact test. Within-group comparisons will be done using the Wilcoxon signed-rank test. P values will be two-sided. Analyses will be conducted by the intention-to-treat method.
NCT01148420 ↗ DMPA & High Dose Oral Progestin (MPA) Tablets in Outpatient Treatment of Acute Excessive Vaginal Bleeding Completed Women's Health Care Clinic, Torrance, California Phase 4 2009-01-01 The purpose of this study is to investigate the effectiveness and acceptability of high dose MPA (20mg oral 3 times a day) for 3 days combined with an injection of DMPA 150 mg intramuscularly in the treatment of acute heavy, prolonged uterine bleeding who have been identified as being eligible for outpatient management
NCT03018249 ↗ Medroxyprogesterone Acetate With or Without Entinostat Before Surgery in Treating Patients With Endometrioid Endometrial Cancer Completed NRG Oncology Early Phase 1 2017-10-11 This randomized surgical window trial evaluates the effect of adding entinostat to medroxyprogesterone acetate before surgery works on progesterone receptors on endometrioid endometrial tumors. Medroxyprogesterone acetate is a progesterone, a hormone produced by body normally. Entinostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving medroxyprogesterone acetate with or without entinostat may effect tumors from endometrioid endometrial cancer.
NCT03018249 ↗ Medroxyprogesterone Acetate With or Without Entinostat Before Surgery in Treating Patients With Endometrioid Endometrial Cancer Completed National Cancer Institute (NCI) Early Phase 1 2017-10-11 This randomized surgical window trial evaluates the effect of adding entinostat to medroxyprogesterone acetate before surgery works on progesterone receptors on endometrioid endometrial tumors. Medroxyprogesterone acetate is a progesterone, a hormone produced by body normally. Entinostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving medroxyprogesterone acetate with or without entinostat may effect tumors from endometrioid endometrial cancer.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for CYCRIN

Condition Name

Condition Name for CYCRIN
Intervention Trials
FIGO Grade 3 Endometrial Endometrioid Adenocarcinoma 1
Grade 1 Endometrial Endometrioid Adenocarcinoma 1
Grade 2 Endometrial Endometrioid Adenocarcinoma 1
Grade 3 Endometrial Endometrioid Adenocarcinoma 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for CYCRIN
Intervention Trials
Hemorrhage 1
Lupus Erythematosus, Systemic 1
Carcinoma, Endometrioid 1
Adenosarcoma 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for CYCRIN

Trials by Country

Trials by Country for CYCRIN
Location Trials
United States 34
Mexico 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for CYCRIN
Location Trials
California 2
Rhode Island 1
Pennsylvania 1
Oklahoma 1
Ohio 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for CYCRIN

Clinical Trial Phase

Clinical Trial Phase for CYCRIN
Clinical Trial Phase Trials
Phase 4 2
Early Phase 1 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for CYCRIN
Clinical Trial Phase Trials
Completed 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for CYCRIN

Sponsor Name

Sponsor Name for CYCRIN
Sponsor Trials
Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran 1
Women's Health Care Clinic, Torrance, California 1
NRG Oncology 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for CYCRIN
Sponsor Trials
Other 3
NIH 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.